Table 3.

Treatment-emergent adverse events reported during multiple-dose administration of rivaroxaban in healthy Chinese subjects

	Rivaroxaban dose
	5 mg b.i.d.	10 mg b.i.d.	20 mg b.i.d.	30 mg b.i.d.	Placebo
	(n= 8)	(n= 8)	(n= 9)	(n= 8)	(n= 8)
Patients with any event, n (%)	5 (63)	2 (25)	3 (33)	3 (38)	3 (38)
Events, n (%)
Gingival bleeding	–	–	–	1 (13)	–
Catheter-site oedema	–	–	1 (11)	–	–
Catheter-site pain	–	–	1 (11)	–	–
Increased ALT	3 (38)	2 (25)	2 (22)	1 (13)	–
Increased AST	–	1 (13)	–	–	–
Increased blood glucose	1 (13)	–	–	–	–
Increased triglycerides	2 (25)	1 (13)	1 (11)	–	3 (38)
Glucose in urine	1 (13)	–	–	–	–
Shoulder pain	1 (13)	–	–	–	–
Haematuria	–	–	–	1 (13)	–

ALT, alanine aminotransferase; AST, aspartate aminotransferase.